Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-24-035375
Filing Date
2024-11-14
Accepted
2024-11-14 17:15:31
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q rvph20240930_10q.htm   iXBRL 10-Q 1226731
2 EXHIBIT 31.1 ex_741515.htm EX-31.1 9605
3 EXHIBIT 31.2 ex_741516.htm EX-31.2 9629
4 EXHIBIT 32.1 ex_741517.htm EX-32.1 7627
  Complete submission text file 0001437749-24-035375.txt   5936051

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rvph-20240930.xsd EX-101.SCH 53585
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20240930_def.xml EX-101.DEF 334692
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20240930_lab.xml EX-101.LAB 276300
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20240930_pre.xml EX-101.PRE 361114
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvph-20240930_cal.xml EX-101.CAL 24088
62 EXTRACTED XBRL INSTANCE DOCUMENT rvph20240930_10q_htm.xml XML 1054858
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38634 | Film No.: 241464295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)